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CASE REPORT
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Vandetanib (ZD6474, Zactima
TM) is a novel, orally available 
inhibitor of different intracellular signaling pathways 
involved in tumor growth, progression, and angiogenesis, 
including vascular endothelial growth factor receptor-2, 
epidermal growth factor receptor, and rearranged during 
transfection tyrosine kinase activity. The most frequently 
reported adverse events attributed to vandetanib include 
diarrhea, elevated aminotransferase, asymptomatic corrected 
QC interval prolongation, and hypertension. In a few 
randomized, double-blinded studies, cutaneous adverse 
events including these general symptoms have been 
reported, but there are only a few reports on the photo-
sensitivity reaction to vandetanib domestically as conducted 
by dermatologists. In this report, we describe two cases of 
photosensitivity reactions induced by vandetanib. After 
improvement with steroid and antihistamine, the photo-
sensitivity reaction was redeveloped by sequential treatment 
with docetaxel. (Ann Dermatol 23(S3) S314∼S318, 2011)
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INTRODUCTION
Drug-related photosensitivity is well established as a valid 
clinical entity
1,2, and is typically activated by exposure to 
either ultraviolet radiation or visible light. Many chemicals 
or drugs have the potential for inducing such phototoxic 
reactions
3-5. Vandetanib is a multi-targeted kinase inhibitor 
that exhibits potent activity against the vascular endo-
thelial growth factor receptor-2 (VEGFR-2), the kinase 
insert domain-containing receptor and, to a lesser extent, 
the epidermal growth factor receptor (EGFR) and rearranged 
during transfection (RET) tyrosine kinase
6,7.
The chemical structure of vandetanib is shown in Fig. 1
7. 
It has increased progression-free survival in studies of 
patients with refractory non-small cell lung cancer and the 
drug is being evaluated as a treatment for other solid 
tumors, including breast, thyroid, prostate, brain, ovarian 
and renal cancers
7,8. It is an orally administered, generally 
well-tolerated drug and the most common adverse effects 
include diarrhea, skin rash, hypertension and asympto-
matic QTc prolongation
6-8. Docetaxel (sanofi-aventis, Taxotere
TM) 
has emerged as one of the most important cytotoxic 
agents and has proven clinical efficacy against many 
cancers
9,10. Docetaxel can cause skin reactions, but there 
are only a few report of photosensitivity reactions
9,10. In 
this report, we describe two patients with cutaneous 
photosensitivity and subsequent pigmentation as related to 
treatment with vandetanib and docetaxel. The patients did 
not recover from the photosensitivity reaction using two 
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Fig. 1. The molecular chemical structure of vandetanib.
Fig. 2. (A∼D) Well-demarcated erythe-
matous pruritic patches and plaques
with a mild scaly appearance on the 
sun- exposed areas (case 1).
CASE REPORT
Case 1
A 67-year-old man was diagnosed with non-small cell 
lung cancer in November 2008. A systemic examination 
revealed left supuraclavicular, high mediastinal, para- 
aortic and left axillary lymph node metastasis, and the 
stage was determined to be T2N3M1. He was treated with 
gemcitabine and cisplatin. After four cycles of combined 
chemotherapy, he was enrolled in a phase II clinical trial 
with oral vandetanib (300 mg/d), which was administered 
in a phase II study (study # D4200C00077) that involved 
patients with non-small cell lung cancer at Gil Hospital, 
Inchen, Korea. One month after vandetanib administra-
tion, the patient visited our department with well-demar-
cated erythematous pruritic patches and plaques, and a 
slightly scaly appearance on the sun-exposed areas of the 
skin, including the neck, anterior chest and both dorsa of 
the hands (Fig. 2). The skin lesions occurred several days 
after the administration of vandetanib, and they gradually 
aggravated. 
During the course of the clinical trial, the patient engaged 
in outdoor activities with adequate sun protection, but did 
not use sun-cream on the skin lesions. A biopsy specimen 
from his neck showed mild hyperkeratosis, dyskeratotic 
epidermal cells, vacuolar degeneration of the basal cells 
and pigmentary incontinence. Superficial perivascular 
edema and a dense lymphohistiocytic infiltration were 
present in the dermis (Fig. 3). A photo test and photo patch 
test were not performed because the patient declined 
further evaluations. He was treated with systemic steroid 
in combination with oral antihistamine and a moderately 
potent topical steroid. After discontinuation of vandetanib, 
the skin lesions improved in a month. His lung cancer 
then aggravated and he was treated with salvage 
chemotherapy that consisted of docetaxel (75 mg/m
2). 
After his second intravenous course of docetaxel, the 
photosensitivity reaction redeveloped, and did not 
improve after discontinuation of docetaxel. He was pre-
scribed oral systemic steroid and antihistamine with 
topical steroid, but the skin lesions did not improve (Fig. 
4). 
Case 2
A 51-year-old man underwent vandetanib therapy for 
non-small lung cancer. He was diagnosed with non-small 
lung cancer in April 2009. After four cycles of combined 
chemotherapy (gemcitabine and cisplatin), he was enrolled YM Son, et al
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Fig. 4. (A∼D) The patient’s photosensitivity and hyperpigmentation were not resolved after discontinuing the docetaxel (case 1).
Fig. 3. The skin biopsy specimen from the neck showed mild 
hyperkeratosis, dyskeratotic epidermal cells, vacuolar degene-
ration of basal cells and pigmentary incontinence. Superficial 
perivascular edema and a dense lymphohistiocytic infiltration 
were present in the dermis (H&E, ×20, case 1).
in a phase II clinical trial with oral vandetanib (300 mg/d), 
which was administered in a phase II study (study # 
D4200C00077) that involved patients with non-small cell 
lung cancer at Gil hospital, Korea. Several days after the 
administration of vandetanib, he presented with erythe-
matous pruritic papule and patches on the sun-exposed 
area of the skin, including the face, neck and both dorsa 
of the hands (Fig. 5A, B). A biopsy specimen from the 
forehead demonstrated hyperkeratotis, dyskeratotic epi-
dermal cells, vacuolar degeneration of the basal cells and 
pigmentary incontinence (Fig. 5C). A photo test and a 
photo patch test were not performed. He was prescribed 
systemic steroids in combination with oral antihistamine 
and a topical steroid. The skin lesions improved in a 
month after discontinuation of vandetanib. After a second 
intravenous course of docetaxel (75 mg/m
2) for salvage 
chemotherapy, the photosensitivity reaction redeveloped. 
Despite treatment with steroid and antihistamine, the skin 
lesions did not improve.
DISCUSSION
Drug-induced photosensitivity refers to the development 
of cutaneous disease as a result of the combined effects of 
a chemical and light
1,2. It is caused by certain chemicals 
or drugs that are applied topically or taken systemically at 
the same time as exposure to ultraviolet radiation or 
visible light
2,3. Exposure to either the chemical or the light 
alone is not sufficient to induce the disease; however, 
when photoactivation of the chemical occurs, one or 
more cutaneous manifestations may arise
3,4.
The photosensitivity reactions may be more specifically 
categorized as being phototoxic or photoallergic in 
nature
1,11. Phototoxicity is much more common than 
photoallergy
3,4,12. Both reactions occur in the sun-exposed 
areas of the skin, including the face, neck and the dorsal 
surfaces of the hands and forearms, but the hair-bearing 
scalp, the postauricular and periorbital areas and the 
submental portion of the chin are usually spared
1-4.
These reactions are not predictable
11,13. They can occur in 
persons of any age, but are more common in adults than 
in children, possibly because adults are usually exposed 
to more medications and topical agents
3,5,12. The degree of 
photosensitivity varies among individuals and not every-
one will have the same impact from a photoreaction
12,13. 
Histologically, phototoxicity is characterized by dermal 
edema, dyskeratosis and necrosis of the keratinocytes
3,14. 
In the case of a severe reaction, the necrosis is pan-Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
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Fig. 5. (A, B) Erythematous pruritic papules and patches on the forehead and both cheeks (case 2). (C) The skin biopsy specimen
from the forehead showed hyperkeratotis, dyskeratotic epidermal cells, vacuolar degeneration of the basal cells and pigmentary 
incontinence (H&E, ×20, case 2).
epidermal
1,4. Epidermal spongiosis with dermal edema 
and a mixed infiltrate consisting of lymphocytes, macro-
phages and neutrophils may be present
2,14. Photoallergic 
reaction is similar to contact dermatitis
1,2,14. Epidermal 
spongiosis with a dermal lymphocytic infiltrate is a 
prominent feature
1,4,14. The biopsy specimens showed 
dyskeratotic epidermal cells and vacuolar degeneration of 
basal cells, and the reactions had a relatively rapid onset, 
which meant that our cases were closer to phototoxicity. 
However, this was not certain as a photo and photo patch 
test were not performed because the patients refused 
further evaluation.
Vandetanib is an orally bioavailable inhibitor of VEGFR, 
EGFR and RET kinases
6,7. Through anti-VEGFR-2 activity, 
it inhibits angiogenesis by decreasing the proliferation, 
migration and survival of endothelial cells
7,8,15. Vande-
tanib was evaluated as a single agent in two phase I 
clinical trials that included patients with advanced refrac-
tory solid tumors
15,16. In the first trial, one patient had a 
photosensitive rash with a 300 mg oral dose of 
vandetanib, but a more detailed description was not 
available
15. In the second study, 13 out of of 18 patients 
developed rashes that included “acne” and photo-
sensitivy
16. Phase II clinical trials on vandetanib are 
currently underway for the treatment of a variety of 
tumors
17,18. Photosensitivity was demonstrated in 23% of 
Japanese patients with non-small cell lung cancer in a 
phase II trial
17.
Vandetanib is a low-molecular weight molecule with a 
polycyclic structure that contains unsaturated double 
bonds (Fig. 1)
6,7. Photosensitizing chemicals usually have 
a low molecular weight (200 to 500 Da) and planar, 
tricylic or polycyclic configurations. They often contain 
heteroatoms that enable resonance stabilizations. Thus, 
vandetanib may be able to induce photosensitivity
9,12,13.
Docetaxel is a semisynthetic taxane, which is a class of 
compounds that inhibit the mitotic spindle apparatus and 
stabilize tubulin polymers
9,10. Docetaxel, either alone or 
in combination with other cytotoxic agents, has been 
effectively used in the treatment of several solid tumors, 
including non-small cell lung cancer and breast cancer
10,19. 
The reported cutaneous reactions with docetaxel are 
usually mild and include erythrodysesthesia, maculo-
papular rash, erythema, desquamation, scleroderma-like 
and lupus-like lesions, alopecia and nail changes
9,19. 
However, of all the reported effects of docetaxel, photo-
sensitivity has only rarely been described previously.
In a previous report, the photosensitivity reaction was 
easily improved several weeks after the discontinuation of 
vandetanib
20, but in our cases, the reaction was not 
resolved after sequential docetaxel treatment. This can be 
a direct toxic effect of docetaxel or an effect of polysorbate 
80 (Tween 80), which is the vehicle for docetaxel
9,10. 
However, there have been few reported photosensitivity 
reactions by docetaxel, so we believe the redevelopment 
of the skin lesions were due to vandetanib or the 
interaction between vandetanib and docetaxel. The mecha-
nisms of interaction and etiology by which the photo-
sensitivity redeveloped by docetaxel are obscure. Further 
evaluation may be required to determine the skin reaction 
caused by vandetanib and docetaxel.
In general, patients with acquired cutaneous photo-
sensitivity should seek the care of dermatologists. We 
report here on two cases of redeveloped photosensitivity 
reaction related to vandetanib and docetaxel. As new 
targeted therapies are developed and introduced into the YM Son, et al
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clinical setting, dermatologists will continue to play an 
important role in diagnosing and managing the novel 
cutaneous adverse effects of these targeted therapies.
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